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Recent increases in attention deficit hyperactivity disorder (ADHD) diagnoses, and the
escalation of stimulant prescriptions, has raised concern about diversion and abuse of
stimulants, as well as the ethics of using these drugs as “cognitive enhancers.” Such
concern appears misplaced in the face of substantial evidence that stimulant drugs
do not improve the academic performance of ADHD-diagnosed students. Moreover,
numerous studies have found little or no benefit of stimulants on neuropsychological
tests of ADHD-diagnosed as well as normal, individuals. This paper examines the
apparent paradox: why don’t drugs that improve “attention,” produce better academic
outcomes in ADHD-diagnosed students? We found that stimulant drugs significantly
improved impairment of episodic memory in ADHD-diagnosed undergraduate students.
Nevertheless, we also found consistent academic deficits between ADHD students
and their non-ADHD counterparts, regardless of whether or not they used stimulant
medications. We reviewed the current literature on the behavioral effects of stimulants, to
try to find an explanation for these conflicting phenomena. Across a variety of behavioral
tasks, stimulants have been shown to reduce emotional reactions to frustration, improve
the ability to detect errors, and increase effortful behavior. However, all of these effects
would presumably enhance academic performance. On the other hand, the drugs were
also found to promote “risky behavior” and to increase susceptibility to environmental
distraction. Such negative effects, including the use of drugs to promote wakefulness
for last minute study, might explain the lack of academic benefit in the “real world,”
despite their cognitive potential. Like many drugs, stimulants influence behavior in multiple
ways, depending on the environmental contingencies. Depending on the circumstances,
stimulants may, or may not, enhance cognition.
Keywords: attention-deficit hyperactivity disorder, cognitive enhancement, episodic memory, stimulants,
amphetamine, methylphenidate
INTRODUCTION
During the last few years the increase in non-medical use
and misuse of the psychostimulant drugs methylphenidate
and amphetamine, prescribed to treat Attention-Deficit/
Hyperactivity Disorder (ADHD), has elicited much discussion
and concern. One analysis of current use argues that the medical
consumption of these two drugs is now comparable to past
stimulant epidemics (Rasmussen, 2008), and implies that the
increase parallels the increased rate of ADHD diagnoses among
children and adults. In support of that interpretation, current
best estimates for an ADHD diagnosis, of 5.9–7.1% in children
and adolescents, and 5.0% in adults, represent 25% and 13.6%
increases, respectively (Kessler et al., 2006; Willcutt, 2012;
Getahun et al., 2013). Nearly 14 million monthly prescriptions
for ADHD were written for Americans ages 20–39 in 2011, two
and a half times the 5.6 million just 4 years before (Schwarz,
2013). In fact, between 1994 and 2009, a substantial increase in
stimulant prescriptions occurred even without a clinical diagnosis
of ADHD, or any other disorder (Olfson et al., 2013). Numerous
surveys of college populations have reported an increase in
stimulant prescriptions and a corresponding escalation of illicit
use (Wilens et al., 2008; Advokat, 2010; Advokat and Vinci, 2012;
Varga, 2012), with lifetime rates of diversion ranging from 5–29%
(Wilens et al., 2008; Smith and Farah, 2011), although accurate
data are difficult to obtain (Ragan et al., 2013).
Studies consistently show that the rationale among students
for using stimulant medications, legally or not, is usually to
improve academic performance, specifically to increase concen-
tration, organization, and the ability to stay up longer and study
(Advokat et al., 2008). Because these reasons for illicit use are not
primarily recreational, it is not always considered to be as prob-
lematic as other types of drug abuse. Unfortunately, this is not
necessarily the case, and the medical and legal consequences of
illicit stimulant use may be underappreciated (Arria et al., 2008;
Arria and DuPont, 2010).
Stimulant diversion and misuse have prompted considerable
debate about the moral implications of using drugs to improve
academic performance. Ethical discussions about taking drugs for
“cognitive enhancement,” have been the subject of numerous edi-
torials and commentaries (Farah et al., 2004; Greely et al., 2008;
Harris, 2009). Thoughtful proposals for the responsible use of
cognitive-enhancing drugs have called for the scientific study of
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the expected risks and the benefits to be gained as well as the
moral consequences of allowing broad access to pharmacological
enhancement of mental capacities.
One practical outcome was the decision of the Ethics, Law and
Humanities Committee of the American Academy of Neurology
(AAN) to release a special report, “Responding to requests from
adult patients for neuroenhancements,” (Larriviere et al., 2009).
According to lead author, Dan Larriviere, “A growing number of
patients without illness believe they can improve their memory,
cognitive focus and attention span by taking neuroenhancement
drugs and are asking for prescriptions.” For the most part, these
“neuroenhancers” consist of stimulant drugs. “The drugs most
commonly used for cognitive enhancement at present are stim-
ulants, namely Ritalin (methylphenidate) and Adderall (mixed
amphetamine salts), and are prescribed mainly for the treatment
of attention deficit hyperactivity disorder (ADHD).” This guide-
line concluded that physicians are allowed to grant requests for
the stimulant drugs to improve cognition in healthy patients,
although they are not obliged to do so. At the 60th Annual
Conference of the Canadian Psychiatric Association in 2010 Dr.
Derryck Smith presented a workshop on the subject and stated
that psychiatrists should not hesitate to prescribe stimulants for
neuroenhancement, if they wish.
The enthusiastic acceptance and embrace of stimulant-
induced cognitive enhancement has not been universal. Outram
(2010), Quednow (2010), and Lucke et al. (2011) argue that
social demand for, and availability of, these drugs may not be as
widespread as supposed, the efficacy of these drugs may be over-
rated, and their adverse psychological and physical effects may
not be fully appreciated. Dr. Eric Racine and colleagues simi-
larly argue against the prescription of medications for cognitive
enhancement in healthy people (Forlini et al., 2012; Szalavitz,
2012; Schwarz, 2012, 2013).
CLINICAL vs. “REAL WORLD” EFFECTS OF STIMULANTS
Ever since amphetamine was discovered, serendipitously in the
1930’s, to reduce hyperactivity in young boys (Baumeister et al.,
2012) there is perhaps no other behavioral disorder than ADHD,
for which drugs have so consistently proven acutely effective.
Stimulants are an effective way of managing ADHD symptoms,
such as short attention span, impulsive behavior, and hyperac-
tivity. These drugs improve ADHD symptoms in about 70% of
adults and 70–80% of children. They tend to reduce interruptive
behavior, fidgeting, and other hyperactive symptoms.
But recent assessments of chronic benefit are less impressive.
In fact, long-term completion rates of adults in clinical trials
have been reported as low as 43–64% (Buitelaar et al., 2012b).
In the first naturalistic study of ADHD-diagnosed adults treated
with drugs for longer than 4 years, the score on a measure of
mental health functioning was not different between those who
were still on treatment and those who were no longer taking the
medications (Lensing et al., 2013). Even in children, treatment
discontinuation is high, with adherence typically ranging “from
36–84.8%” (Toomey et al., 2012, p. 763). The main reasons for
discontinuation were “psychological side effects” (mood changes,
irritability, depression, personality changes) and “perceived inad-
equate effectiveness.” Comparable results were reported in a
review of medication adherence in adults with ADHD. While
acknowledging the difficulty of accurately determining adherence
rates, estimates ranged from 52–87% (Caisley and Müller, 2012).
This was especially noteworthy because, as adults, the patients in
these reports often took their medication “as needed,” and were
not required to use the drugs every day. In a similar review of ran-
domized clinical trials in adults, Castells et al. (2013) found the
rate of all-cause treatment discontinuation of methylphenidate
was not statistically different from placebo. This was in spite of
the fact that methylphenidate was more efficacious than placebo
in reducing symptoms.
In brief, even when the drugs are effective in reducing symp-
toms, ADHD patients often discontinue their stimulant medi-
cations. A recent study of this issue found that improvement in
ADHD inattention and severity rating scores were not associated
with functional improvement (Buitelaar et al., 2012a). In other
words, symptom reduction does not always improve quality of
life. As stated in one recent paper “While . . . results show that
stimulants are effective in reducing symptoms of ADHD in adults,
uncertainties remain as to their efficacy on other key aspects of the
clinical picture” (Biederman et al., 2011, p. 509).
There is a similar disparity between the efficacy of stimu-
lants, either amphetamine or methylphenidate formulations, for
ADHD symptoms and their effect on cognitive performance.
Reviews of this topic (de Jongh et al., 2008; Advokat, 2010;
Repantis et al., 2010; Bidwell et al., 2011; Smith and Farah, 2011;
Swanson et al., 2011; Advokat and Vinci, 2012) offer surpris-
ingly little experimental support for stimulant-induced cognitive
enhancement, not only in those with ADHD but also in nor-
mal individuals (Quednow, 2010). Articles in the New Yorker
(Talbot, 2009) and Scientific American (Stix, 2009), describing
the resurgence of these agents confirm the modest intellectual
benefit derived from their “real world” use. The most recent
review of long-term ADHD medication on academic outcomes
in youth (Langberg and Becker, 2012) confirmed these earlier
conclusions. As with all previous reviews, they found modest,
but clinically unimpressive, improvement in several areas, includ-
ing achievement test scores, grades, and grade retention. Ilieva
et al. (2013) conducted a comprehensive investigation of the neu-
ropsychological effects of mixed amphetamine salts in healthy,
non-ADHD, young adults. They administered a battery of 13
tests, over 7 sessions, including standard memory assessments
(face and word recognition), digit-span and n-back tests, tests
of inhibitory control (Go/No-Go, Flanker task), of creativity
(remote associations, embedded figures), standardized achieve-
ment tests, and a question about whether the participant felt that
the drug influenced their performance. No cognitive outcome was
enhanced (although, as often reported with stimulants, there was
some slight improvement in those with lower baselines). Despite
this objective outcome, participants believed their performance
was more enhanced by the drug than by the placebo.
In brief, concern about the recent resurgence in illicit stimulant
use and the ethics of stimulants as cognitive enhancers is ironic
given the lack of evidence that they actually do enhance cognition.
But this raises the question: Why do drugs that acutely increase
attention and concentration produce so little long-term intellectual
benefit?
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EFFECTS OF STIMULANT MEDICATIONS ON COGNITIVE MEASURES IN
ADHD-DIAGNOSED UNDERGRADUATES
For several years, we have conducted studies in college under-
graduates to address this question. In one set of experiments,
neuropsychological tests were administered to control groups,
(students who did not have ADHD) and to groups of students
with ADHD who were tested when they were either “on” or
“off” their medication. We used several types of tasks, ranging
from motor dexterity, saccadic eye movements, attention, verbal
fluency, memory (acquisition and retention of word lists), dis-
tractibility, and problem solving (Barrilleaux and Advokat, 2009;
Advokat and Vinci, 2012).
In general, ADHD-diagnosed college students were not
severely impaired on these tests relative to their normal peers.
This was not surprising; all participants had been admitted to
an accredited 4-year college. Because we did not do any assess-
ments to confirm the diagnoses, it is reasonable to assume that
some unknown proportion of the diagnoses were questionable.
Even though we required that all participants provide a prescrip-
tion for stimulants before they could be accepted into the study,
we did not validate their diagnoses. On the other hand, the pre-
sumed cognitive effect of stimulants is not thought to be restricted
to the ADHDpopulation. Stimulants are also assumed to be capa-
ble of improving intellectual performance in cognitively normal
individuals, although they usually are more effective if the base-
line measure is below normal. In other words, we should have
been able to detect some improvement even if the ADHD diag-
noses were not valid. For that matter, it was also possible that
some of the non-ADHD control group might have correctly been
diagnosed with ADHD if they had been evaluated.
Our results can be summarized as follows: First, consistent
with ADHD symptomatology, non-medicated ADHD students
were more likely to be impaired on tasks that required some
type of inhibitory reaction, in which they had to withhold their
responses until the correct choice could be made (Barrilleaux and
Advokat, 2009). Second, in most of our procedures, although per-
formance was improved by stimulants, the amount of improve-
ment was usually not significantly different from the normal,
control, level. That is, ADHD-diagnosed students often did better
on the neuropsychological tasks when they were on their medica-
tion, relative to when they were not. But, in most cases, neither
result was different from the performance of normal students.
Third, in those cases where the drugs did improve performance,
the result was not due to the fact that stimulant drugs simply
made the responses faster; it occurred whether the drug increased
or decreased reaction times. It is not surprising that the most reli-
able effect of stimulants in our studies, as well as that of others
(Advokat, 2010; Advokat and Vinci, 2012), is to reduce impul-
sivity, since that is one of the reasons they are prescribed. In fact,
these drugs also reduce impulsivity in healthy adults (deWit et al.,
2002). But, a decrease in impulsivity would presumably be a ben-
eficial effect; it would not explain why the drugs don’t improve
academic outcomes.
We then considered another alternative. Academic environ-
ments are inherently anxiety provoking, and arousal is known to
affect memory. Modest levels can improve memory but too much
anxiety will impair memory. This classic behavioral principle,
known as the Yerkes-Dodson law, is often expressed in the form
of an inverted inverted-U function. While it may not be sup-
ported in all types of situations, this relationship is more likely to
be obtained with uncomplicated, simple, tasks. We hypothesized
that perhaps adding a stimulating drug to the normal academic
stresses of college produced too much arousal and impaired per-
formance. To test this, we adapted a procedure developed by
Cahill and McGaugh (1995) and used by Brignell et al. (2007),
to study the effect of stimulants on episodic memory. The pro-
cedure consists of presenting a narrative slideshow that contains
neutral passages and an emotional segment in the middle of the
story. Participants watch the slides and listen to the story. Several
days later they are asked questions about the narrative, to see how
much they recall. Inevitably, information from the emotional seg-
ments is recalled more accurately than the neutral segments. We
gave the same narrative slideshow to a group of normal students,
and two groups of ADHD students, who were either on or off
their medications. One week later all the students returned, under
the same medication status, to answer questions about the story
(Maul and Advokat, 2013). Figure 1 shows the percent of cor-
rectly answered questions in each group as a function of the story
phase.
As expected, the control (non-ADHD), group recalled the
“emotional” parts of the story significantly better than the
“neutral” story segments. The data also show, for the first time,
this “inverted-U shape” recall function in ADHD-diagnosed par-
ticipants regardless of whether they were tested while on or off
their medication.We appreciate that, in contrast to the classic def-
inition, we cannot conclude that the descending limb of the U is
due to a continued increase in arousal during the second neu-
tral story segment. The outcome mainly illustrates an example of
emotionally enhanced recall, which occurred reliably in all three
groups.
In addition, the figure also shows that the performance of the
non-medicated ADHD groupwas worse than the other groups on
both, the first neutral segment, and on the emotional segment.
Last, the score of the non-medicated group on the final segment
FIGURE 1 | Story recall of control and ADHD adults. Average score of
each group in each story phase. ∗Significant difference within each group
across the 3 story phases; ∗∗Significant difference among the 3 groups on
the Emotional Slide questions.
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was the same as that of the other two groups and was significantly
better than on their first neutral phase.
These data show a substantial improvement, essentially
normalization, of long-term, episodic, memory in medicated
ADHD diagnosed adults. This result provides clear-cut evidence
of cognitive benefit from stimulant drugs, and is one of the
most dramatic examples of memory improvement demonstrated
by stimulants. The results are reminiscent of Izquierdo et al.
(2008), who found that subjects over 35–40 years old were sig-
nificantly less likely to remember details about information they
had learned 7 days before, relative to younger subjects. After
methylphenidate, only the older subjects showed improvement;
their age-related memory deficit was reversed, and they remem-
bered asmuch information as the younger subjects. [Interestingly,
episodic memory (of visual scenes) has also been improved in
older adults (65–75 years old), when tested 6 h after receiving
the dopamine precursor, levodopa (Chowdhury et al., 2012). Like
stimulants, levodopa increases brain levels of the transmitter,
dopamine].
In summary, our results show that stimulant medications can
improve episodic memory in ADHD-diagnosed adults. Like the
outcome of the neuropsychological assessments, the data suggest
that the drugs do have some cognitive benefit. That is, in addi-
tion to their well-known ability to enhance attention, we found
that stimulant drugs can also improve episodic recall. Again, how-
ever, this does not explain why they do not improve academic
performance.
EFFECTS OF STIMULANT MEDICATIONS ON ACADEMIC
PERFORMANCE OF ADHD-DIAGNOSED UNDERGRADUATES
Because they were college students, our presumptive ADHD pop-
ulation was perhaps not representative of the typical ADHDadult.
Maybe they had learned how to gain some academic benefit
from the stimulants. If that were true, they might not be aca-
demically impaired, relative to their non-ADHD counterparts.
To find out more about the respective academic behavior of our
undergraduates, we conducted a couple of surveys.
In the first study (Advokat et al., 2008) we surveyed three
groups, ADHD-diagnosed students, non-ADHD, normal stu-
dents, and a second group of non-ADHD, normal, students who
acknowledged that they used the stimulants illicitly. First, we
found that these three groups differed significantly in response
to the question: “Do ADHD medications help academic perfor-
mance.” A significantly greater proportion of the ADHD (and the
normal/illicit use group), endorsed this statement compared with
the normal group. This is consistent with the results reported by
Ilieva et al. (2013), showing that their participants believed that
stimulants improved their cognitive performance. Most impor-
tant, the groups in our study also differed significantly in Grade
Point Average (GPA), in that the GPA of the ADHD group (3.05,
out of a possible 4.0) was significantly lower than that of the
normal group (3.19).
Of course, we couldn’t tell from these data how many stu-
dents in the ADHD group actually used stimulant medications.
Nor could we tell if the GPA would be even lower if those stu-
dents didn’t use the drugs. That is, we couldn’t tell if the drugs
were effective, either because they worked or because the students
believed the drugs worked. To find out more about the influence
of stimulant medications on academic outcome we next surveyed
the self-reported study habits and strategies of ADHD-diagnosed
and normal undergraduates (Advokat et al., 2011).
Our data showed that on average ADHD participants were
diagnosed about 5 years before entering college.While nearly 98%
of that group had initially taken ADHD medication, only 78.3%
were currently using the drugs, while 19.6% stated that they
were not (some respondents didn’t answer all questions). When
asked why they stopped taking stimulant medications, the major-
ity cited side effects. Although specific side effects weren’t always
mentioned (“I did not like the way it made me feel; . . .make
me feel crappy; the negative side effects outweigh the positives”),
some individuals cited headaches, irritability, temporary heart
rate elevation, nausea, sleep interference and “antisocial” feelings
as examples of undesirable reactions. A few also stated that they
either didn’t need the drugs anymore, or, they wanted to see if
they didn’t need them anymore. Similar to the previous study,
more than 90% of the students with ADHD endorsed the state-
ment that medications helped them academically. Most of them
stated that the drugs helped them to focus or to concentrate bet-
ter, to pay attention, stay awake, and organize their studying.
However, relatively few students (n = 6 out of more than 90)
with ADHD specifically stated that they took medication to avoid
distractions.
ADHD and non-ADHD undergraduates did not differ in their
scores on the Scholastic Aptitude Test (SAT), Advanced Placement
credits, scholarship awards, course credits, or number of hours
they studied per week. Students in both groups believed they
studied about the same as their peers, that the quality of their
notes was the same, and stated that they rarely reviewed their class
notes or read assigned readings before class.
However, the two groups did differ on several academic mea-
sures. As in our first study, the college GPAs of ADHD students
were statistically lower than that of the Controls (2.94 vs. 3.12)
and they also had significantly lower high school GPA and ACT
scores (American College Testing is a standardized test for high
school achievement and college admissions in the United States
produced by ACT, Inc.). Although small, this difference was statis-
tically significant, in spite of the fact that a minimum high school
GPA and ACT score were required for university admission.
ADHD students were also significantly more likely to withdraw
from a class, to say that they were worse than other students
at planning for and in completing class assignments, in their
frequency of taking class notes, and in avoiding distractions.
One of the questions we asked in this survey was whether stu-
dents studied “ahead of time” for exams, or whether they waited
until just before the test to prepare. We then looked at how this
related to their GPA. The results are shown in Table 1.
The data in Table 1 show that the GPAs of non-ADHD stu-
dents were the same whether or not they studied “ahead of time”
for an exam. In other words, normal students did not “pay a price”
in GPA for waiting until a few days before exams to study. In con-
trast, ADHD students who studied “well before” an exam had
higher GPAs than those (the majority of this group) who didn’t.
Unlike normal students, ADHD students did “pay a price” if they
waited until the last minute to study. Admittedly, this question
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did not distinguish among the possible types of exams (such as
multiple choice or essay), nor did it take into account the level of
knowledge that was assessed (such as application or synthesis). So
we don’t know if the students’ preparationmight differ depending
on the nature of the assessments.
We then looked at whether the stimulant medications had any
effect on the GPA of ADHD-diagnosed students as a function
of whether they studied ahead of time or waited until the last
minute. These data are shown in Table 2.
A two-way analysis of these GPAs found no effect of med-
ication, but a statistically significant effect of study interval,
(F = 4.06, p = 0.047). This result showed that, if ADHD students
utilized the well-known strategy of studying ahead of time for
exams, they could overcome their achievement deficit, even if they
didn’t take stimulant medications. In spite of the fact that only
three ADHD students “studied ahead of time” without using the
drugs, their GPAwas comparable to that of the 19 undergraduates
who did take the drugs in addition to using good study habits.
These data suggest that the GPA disparity between ADHD and
non-ADHD students could be eliminated if ADHD students were
able to develop well-established study habits. The results imply
that the drugs alone are not sufficient to overcome the disadvan-
tage of not preparing for exams. Unfortunately, it is not clear from
these data alone if taking stimulant medications actually helps
ADHD students to do that. That is, do the stimulant drugs help
students to plan ahead, or to begin studying ahead of time so that
they can compensate for their cognitive deficit? If so, why didn’t
more of the ADHD students do that?
It should be noted that evenwithout good study habits, ADHD
students were not failing. Their average GPA was just above a
“C,” which means they were able to progress toward graduation
at a normal pace. On the other hand, the absolute difference
between the GPAs of ADHD students and normal students was
numerically small. Even if the stimulants only increased energy
and promoted wakefulness, it might be expected that they could
bridge the gap. Why don’t they?
Table 1 | GPA as a function of study habits in ADHD and Non-ADHD
undergraduates.
When you study for
an exam do you:
Non-ADHD (n) ADHD (n)
Study well before the exam? 3.12 (56) 3.16 (22)
Study in the day or two before the exam? 3.10 (86) 2.86 (64)
ns p < 0.05
Table 2 | GPA of ADHD students: relationship between study habits
and medication.
Study ahead of time? Take medication?
Yes (n) No (n)
Yes 3.15 (19) 3.19 (3)
No 2.88 (47) 2.84 (15)
NON-COGNITIVE BEHAVIORAL EFFECTS OF STIMULANT
MEDICATIONS
Perhaps the problem lies with non-cognitive effects of stimu-
lants. For example, these drugs are abused for their presumed
euphoric effects. As McCloskey et al. (2010) point out, impul-
siveness is often linked to abuse susceptibility; perhaps more
impulsive individuals might experience greater euphoria from
drugs, which might impair their ability to concentrate. They
tested this by using a reaction time task, and comparing the sub-
jective responses of normal adults, with their attention lapses,
under amphetamine. In contrast to the prediction, participants
with greater lapses of attention liked amphetamine less than
those with fewer lapses, suggesting that ADHD students might
be less affected by the euphoric properties of the stimulants than
non-ADHD students.
What about other, non-cognitive, deficits in ADHD (Retz
et al., 2012)? Emotional dysregulation, such as difficulty in deal-
ing with stressful situations, excessive irritability and excitability,
is also a symptom of the disorder. Emotional volatility may play
a role, for example, in the increased risk of unsafe driving and
traffic accidents in ADHD adults. While poor driving may be
caused by inattention, it is also related to greater negative affect
and increased frustration and anger in ADHD adults (Oliver
et al., 2012). Studies of either simulated (Biederman et al., 2012)
or real driving performance in ADHD adults (Cox et al., 2012)
show significant improvement with stimulant drugs. Whether
this occurs from increased attention or decreased frustration, or
both, remains to be seen. But decreased frustration would pre-
sumably improve, or at least not impair, academic performance.
The ability to monitor and regulate one’s actions is also
thought to be impaired in ADHD. Hester and colleagues (2012)
assessed this by adapting the standard “go/no-go” task, to make
the inhibitory response more difficult and elicit more errors.
In this procedure, participants indicate when they realize they
made a mistake in responding. O’Connell et al. (2009) had previ-
ously found that ADHD participants were less likely than normal
adults to recognize when they made an error. Hester et al. (2012)
showed, in healthy adults that methylphenidate increased accu-
racy and significantly increased the proportion of errors that
participants were aware of. Again, the direction of this drug effect
would predict cognitive improvement with stimulants.
Yet another deficit associated with ADHD is a difficulty in sus-
taining effort. This is seen in the inability to complete projects and
maintain academic or professional performance over long dura-
tions. To study this impairment deWit and colleagues developed
an experimental protocol that required participants to choose
whether to respond at a low rate to earn a low amount of money,
or to respond at higher rates to earn more money. In either case,
the probability of winning the money varied from high (88%) to
medium (50%) to low (12%). In normal adults, amphetamine
selectively increased the proportion of high rates of responding
on the low probability trials. This was interpreted tomean that the
stimulant selectively increased willingness to work harder, partic-
ularly when the probabilities are low (Wardle et al., 2011). Again,
however, to the extent that this elegant paradigm is relevant to
ADHD, the results would predict that stimulants should improve
academic performance.
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There are, however, some experimental paradigms in which
stimulants worsen performance. Campbell-Meiklejohn et al.
(2012a) devised a gambling game, in which participants had to
choose, on each trial, whether they would risk a certain amount
of money (the “stake”) after first starting out with a specified
monetary loss. If the participant chose to play, and won, they
would double their stake and previous losses were recovered. If
they lost, the stake was lost and that amount was added to pre-
vious losses. The probability of winning varied, although this
information was not given to the participants. Placebo players
gambled less as the amount of the stake and the loss increased.
However, participants given methylphenidate gambled at a con-
sistent rate, which was above chance, and which remained the
same across all stakes and trials. These results were similar to a
study using rats (St. Onge et al., 2010) in which amphetamine
also significantly appeared to increase “risky choice” compared
to saline.
The data of Campbell-Meiklejohn et al. (2012a) were
interpreted to mean that the stimulant “disrupted inhibitory
influences on risky choice,” because participants who got
methylphenidate did not reduce their gambling as the stakes and
losses increased. However, these data might also suggest that
stimulants impair “cognitive flexibility,” because behavior under
methylphenidate did not seem responsive to changing contingen-
cies. Impairment of cognitive flexibility, or “cognitive constric-
tion,” was proposedmany years ago as one cause of poor academic
outcomes in stimulant-treated ADHD children (Advokat, 2010).
A similar decrease in “cognitive flexibility,” might also help
explain results of another study by Campbell-Meiklejohn and col-
leagues (2012b). In that experiment, methylphenidate, given to
normal adults, appeared to promote behavior that conformed
to “social norms.” Regardless of the interpretation, Campbell-
Meiklejohn et al. (2012a) suggest, and we agree, that this type of
drug effect might be relevant to the issue of stimulant-induced
cognitive enhancement.
While the Campbell-Meiklejohn studies involved normal par-
ticipants, Agay et al. (2010) directly compared adults with
ADHD and healthy control participants on two versions of
the Iowa Gambling Task. On the standard version, there was
no effect of methylphenidate in either ADHD or non-ADHD
participants. Each group made the same proportion of poor
choices. On a modified version, ADHD participants made more
risky choices than non-ADHD participants, which indicated
a greater susceptibility to distraction. Oddly, methylphenidate
had no effect on ADHD participants, but the drug increased
the proportion of risky choices made by the non-ADHD,
control, group. These data are consistent with the studies
of St. Onge and Campbell-Meiklejohn, in showing that, in
normal persons stimulants increase risky behavior (or pro-
mote inflexibility). But, because the stimulant did not improve
the performance of ADHD participants, the authors specu-
lated that, in environments that are very distracting, ADHD
promotes poor decision-making and apparently the drugs
don’t help.
Results of a study by Prehn-Kristensen et al. (2011) also show
that stimulants can worsen the effect of distractions. Although
this study involved children (approximately 13–14 years old),
and may not generalize to adults, the data show that adding a
distracting stimulus to a working memory procedure impaired
performance only when the ADHD group was on medication.
Distracting stimuli did not reduce accuracy of either healthy
controls or ADHD patients when they were off their medication.
SUMMARY AND CONCLUSIONS
Our research attempted to address the paradox of why drugs
described as “cognitive enhancers” did not improve long-term
academic performance of college students. Consistent with pre-
vious reports in adults with ADHD, we found minimal deficits
on neuropsychological tests, and verymodest improvements from
stimulants. On the other hand, we discovered a substantial deficit
in episodic memory in ADHD undergraduates, which was elim-
inated with stimulant medications. Whether or not this phe-
nomenon would also occur in non-ADHD individuals remains to
be seen. It might be that stimulant-induced facilitation of episodic
memory will only occur when there is some baseline deficit, as is
often the case with these drugs.
We also found the same academic impairment in ADHD col-
lege students previously reported in children and adolescents with
the disorder.We further showed that in spite of the small absolute
quantitative differences between these two groups, their deficits
were not eliminated by stimulants alone.Moreover, our data show
that, conversely, even without the stimulant drugs, ADHD under-
graduates are capable of performing just as well in college as
their non-ADHD peers, if they acquire well-established effective
study habits. While these results increase our knowledge of ADHD
related cognitive impairment, they do not explain why ADHD
undergraduates, as a group, do not match their peers in academic
performance.
To address that question we considered some non-cognitive
behavioral effects of stimulants on mood and motivation. We
found evidence that stimulants reduce frustration, improve self-
regulation, and increase effortful behavior, and that the drugs’
euphoric effects do not necessarily impair attention. However, all
of these actions would facilitate academic performance and would
not explain the discrepancy.
On the other hand, we also found evidence that stimulants
“promote risky behavior” and may increase the interfering effect
of environmental distractions. Results concerning risky behavior
might be reinterpreted as evidence of stimulant-induced “inflex-
ibility,” or “cognitive stereotopy,” which have been recognized for
a long time (Robbins and Sahakian, 1979). Nevertheless, it may
be that some students, either consciously or not, use these effects
to their advantage. For example, the “inflexibility” that may be
induced by stimulants might be put to good use by promoting
a consistent, habitual, study schedule. Perhaps stimulant-induced
facilitation of episodic memory does benefit ADHD students with
good study habits. Alternatively, the drugs may not have much
benefit if students use them to stay up longer the night before
exams, or to write papers at the last minute. While we have not
been able to definitively answer the question of why cognitive
enhancers do not promote better academic outcomes, perhaps
our results have helped reframe the issue for future research,
so that policy decisions about substance abuse and cognitive
enhancement might be better informed.
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